Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
VWAGY Volkswagen AG
MLVF Malvern Bancorp Inc
GBCI Glacier Bancorp Inc
Go

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
$2.39
Day's Change
-0.01 (-0.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.60
Day's Low
2.17
Volume
(Heavy Day)
Volume:
816,733

10-day average volume:
173,568
816,733

Coinbase stock careens toward worst drop on record but fears are 'greatly overblown,' says analyst

8:36 am ET May 12, 2022 (MarketWatch)
Print

By Emily Bary

Analysts kept their overwhelmingly bullish views on Coinbase in the wake of disappointing earnings

Shares of Coinbase Global Inc. were cratering Wednesday after the cryptocurrency marketplace delivered a disappointing earnings report amid a slowdown in the trading of digital assets.

The company saw a sharp drop-off in the number of monthly users transacting on its platform during the most recent quarter, and it disclosed that it expected to see even fewer such users in the current period. Its shares were tumbling 26% in Wednesday afternoon trading and on track to log their worst single-day percentage drop on record.

Despite the bleaker near-term outlook for the crypto marketplace, analysts overwhelmingly kept their bullish views on the company. While at least 13 brought down their price targets, by an average of 40%, none tracked by FactSet opted to downgrade the stock in the wake of Coinbase's (COIN) recent results.

Of the 28 tracked by FactSet who follow Coinbase, 20 have buy ratings, six have hold ratings, and two have sell ratings.

Coinbase's management team sounded optimistic in the face of near-term challenges to the business, with Chief Executive Brian Armstrong saying on the company's earnings call that the down period presented "a big opportunity because we're greedy when others are fearful.

"We tend to be able to acquire great talent during those periods and others pivot, they get distracted, they get discouraged," he said. "So we tend to do our best work in a down period."

The company is continuing with its plans to make 2022 an investment year.

At least some of the bullish analysts seemed to buy into that view.

In a note titled "What Doesn't Kill COIN Makes COIN Stronger," D.A. Davidson's Christopher Brendler wrote that his estimates "again fall materially" but added that he and his team "agree in management's commitment to growth and believe investor patience will be rewarded."

He kept a buy rating on the stock but reduced his price target to $135 from $160.

BTIG's Mark Palmer said that the concerns driving Coinbase's sharp selloff following the report "appear greatly overblown in light of liquidity and long-term growth prospects."

Palmer noted that he is "clear-eyed regarding the potential impact of a severe Federal Reserve tightening cycle and the potential for that cycle to result in an economic recession," though he said that Coinbase's stock price fails to give the company credit for its "ample liquid assets," such as $6.1 billion in cash and equivalents, along with roughly $1 billion in crypto held for investment.

It also "ignores" Coinbase's leadership position and its newer initiatives such as a marketplace for non-fungible tokens (NFTs).

He reiterated a buy rating on the stock but cut his price target to $380 from $500 in the face of near-term headwinds.

"At the same time, we believe it is highly likely that investors at some point in the not-too-distant future will look back on the levels at which COIN was trading today and wonder how it ever reached those lows given the company's ample resources and its significantly advantaged position within the crypto space," Palmer wrote.

Needham's John Todaro also focused on what he saw as the bigger picture.

"Blockchain rewards could see a larger impact in the back half of the year as well as in subsequent years following the rise of proof-of-stake tokens," he wrote. "Further, we believe crypto adoption over the long term will accelerate and that Coinbase is the best retail on-ramp existing today."

Todaro has a buy rating on the shares, though he reduced his target price to $173 from $360.

Those analysts who had been on the sidelines heading into the report were less optimistic, however.

"While the long waitlist to join the NFT platform can generate positive headlines, the party may be short-lived as NFT interest continues to fade," wrote Mizuho's Dan Dolev, who has a neutral rating on the shares and lowered his price target to $135 from $150.

Bernstein's Harshita Rawat said that Coinbase has been "over-earning" in terms of the fees it charges and the "hundreds of dollars" in average revenue per use that it generates, based on fees and high trading volume.

"So COIN's growth (even outside of broader crypto market performance) is limited by disposable incomes of consumers, and intensifying competition from crypto-native peers and fintechs," she wrote. "The exception here, of course, is revenue diversification beyond crypto trading, which is in early innings (e.g., a lot of work to do on NFTs) and also somewhat linked to crypto asset prices (e.g., custody, staking) -- as we saw this quarter."

She kept a market perform rating on the shares, while cutting her price target to $80 from $200 in a note titled: "Defiantly spending in the face of a potential crypto winter. Bold or imprudent?"

"Although we understand the desire to reinvest to dominate the Web3 user interface (and monetization), we also worry whether increased investments are an outcome of greater competitive pressures," he wrote. "Competition is, in fact, intensifying in almost all areas of COIN's business."

-Emily Bary

	

(END) Dow Jones Newswires

May 12, 2022 08:36 ET (12:36 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.